Glucagon ELISA

(10-1271-01)

Kit format: 1 x 96 wells

Measurement range: 1.5 – 130 pmol/L (5 – 453 pg/mL)

No cross-reactivity to glicentin, proglucagon 1-16, and glucagon 3-29

CE/IVD labeled on select markets

No purification of samples

Highly appreciated and often cited assay

Controls available: 10-1286-01

TALK TO A PERSON

Description

The Mercodia Glucagon ELISA is a CE/IVD-labelled, highly specific and sensitive immunoassay for measuring glucagon in plasma and serum.

The highly specific monoclonal antibodies used in this assay enable accurate determination of glucagon without significant cross-reactivity to other circulating pro-glucagon-derived peptides, e.g. glicentin.

As of October 1st, 2020, the assay protocol of Mercodia Glucagon ELISA 10-1271-01 is updated to make the sequential protocol default, abolishing cross-reactivity to glicentin. To run the old, simultaneous protocol, please refer to Technical Note TN34-161.

Test characteristics

Species

Human

Sample volume

25 µL

Sample types

Serum, EDTA plasma and cell culture medium

Assay range

1.5-130 pmol/L (5.95-453pg/mL)

Detection limit

≤0.75 pmol/L

Incubation

18-22 h (overnight) + 1 h + 30 min

Detection method

Absorbance

specificity

The following cross-reactions have been tested:

Glicentin

Not detected

Oxyntomodulin

4.0 %

Proglucagon (1-61)

Not detected

Glucagon (3-29)

Not detected

directions for use & Safety Data Sheet

Directions for Use - 10-1271-01 Version 12.0 Lot.no 32229, 31792, 32837, 33191, 33439, 33986, 35184, 35430

Safety Data Sheet - 10-1271-01

For other languages and older versions:

Technical Library

technical notes

For product-specific technical notes see:
TN34-0146 Sample collection and handling with Mercodia Glucagon ELISAs
TN34-0161 Simultaneous protocol for Mercodia Glucagon ELISA (10-1271-01)

For other technical notes see our Technical Library

references

Kahn, S.E. et al. (2021). Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, Jun; dc210460. Read more >

Zhu, X. et al. (2021). SGLT2i increased the plasma fasting glucagon level in patients with diabetes: A meta-analysis. European Journal of Pharmacology, 903, 174145 Read more >

Bevacqua, R. J. et al. (2021). CRISPR-based genome editing in primary human pancreatic islet cells. Nature Communications, 12(1), 2397. Read more >

Alexiadou, K. et al. (2020). Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. BMJ open diabetes research & care, 8(1), e001076. Read more >

Stern, J. H. et al. (2019) Obesity dysregulates fasting-induced changes in glucagon secretion. J. Endocrinol. 243(2), 149–1606. Read more >

Roberts GP et al (2018) Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery. Surg Obes Relat Dis May;14(5):562-5682. Read more >

Gar, C. et al. (2018) Patterns of plasma glucagon dynamics do not match metabolic phenotypes in young women. J. Clin. Endocrinol. Metab. 103, 972–982. Read more >

Raffort, J. et al. (2017) Fasting Circulating Glicentin Increases After Bariatric Surgery. Obes Surg 27:1581–1588. Read more >

Miyachi, A. et al. (2017) Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays. Anal. Bioanal. Chem. 409, 5911–5918. Read more >

Wewer Albrechtsen, N. J. et al. (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57, 1919–1926. Read more >